Scarica l'app Stockscreener
0.7086
3.23%
0.0222
Dopo l'orario di chiusura:
.73
0.0214
+3.02%
Precedente Chiudi:
$0.6864
Aprire:
$0.67
Volume 24 ore:
432.79K
Relative Volume:
0.36
Capitalizzazione di mercato:
$23.58M
Reddito:
-
Utile/perdita netta:
$-55.73M
Rapporto P/E:
-0.2196
EPS:
-3.2274
Flusso di cassa netto:
$-68.87M
1 W Prestazione:
+1.27%
1M Prestazione:
+6.48%
6M Prestazione:
-50.10%
1 anno Prestazione:
-73.66%
Intervallo 1D:
$0.6642
$0.71
Intervallo di 1 settimana:
$0.6346
$0.74
Portata 52W:
$0.3151
$2.78
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
0.7086 | 23.00M | 0 | -55.73M | -68.87M | -3.2274 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-23 | Ripresa | UBS | Neutral |
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-07-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-09-09 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-08 | Iniziato | BTIG Research | Buy |
| 2024-06-27 | Iniziato | Stifel | Buy |
| 2024-05-06 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-03 | Iniziato | Evercore ISI | Outperform |
| 2024-03-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-03-18 | Iniziato | TD Cowen | Outperform |
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Wenru Song Net Worth (2026) - GuruFocus
Kira Pharmaceuticals - The Pharma Letter
Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Velan group shifts to passive stake in Jasper (NASDAQ: JSPR) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Jasper Therapeutics beats Q2 expectations but shares fall after results - Yahoo Finance
Jasper Therapeutics beats earnings expectations but stock falls 4% By Investing.com - Investing.com South Africa
Jasper Therapeutics beats earnings expectations but stock falls 4% - Investing.com
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - marketscreener.com
JSPR Q1 2026 Earnings: 91.94% EPS Beat Signals Cost Discipline, But Stock Slips 8.46%Earnings Season Preview - vinanet.vn
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
JSPR Financials: Income Statement, Balance Sheet & Cash Flow | Jasper Therapeutics Inc - Stock Titan
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2 - Moomoo
Piper Sandler initiates Jasper Therapeutics stock at overweight By Investing.com - Investing.com Canada
$Jasper Therapeutics (JSPR.US)$ Goodbye - Moomoo
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Jasper Therapeutics Inc (JSPR) Stock News Today - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives? - Kalkine Media
JSPR Q1 2026 Earnings: Loss Narrowly Beats Estimates, Shares Surge 12.95%Dividend Increase Stocks - vinanet.vn
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirt - The National Law Review
JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst - TipRanks
Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know - TipRanks
JSPR Q2'26 Earnings: EPS estimate is (0.25) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therap - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors - marketscreener.com
Jasper Therapeutics (JSPR) completes $131.9M Rule 506(b) private equity sale - Stock Titan
Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director - Stock Titan
Jasper Therapeutics (JSPR) awards 7,500 stock options to board director - Stock Titan
Jasper Therapeutics (JSPR) grants 7,500-share stock option to board director - Stock Titan
Jasper Therapeutics (JSPR) grants director option for 7,500 shares - stocktitan.net
Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan - The Globe and Mail
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes - Stock Titan
JSPR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) Slips to $0.62 as Stock Tests Key SupportFibonacci Arc - dars.gov.et
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Date & Reports & Earnings News - TradingKey
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Jasper Therapeutics Inc Azioni (JSPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):